-
Sun Yat-sen University Researchers Develop AI Model for Early Ovarian Cancer Detection
•
Researchers at Guangzhou’s Sun Yat-sen University Cancer Center have made a significant breakthrough with the development of an artificial intelligence (AI)-based model designed for the early detection of ovarian cancer. This cost-effective AI model aims to assist in diagnosing the deadliest form of gynecological cancer worldwide. In China, early-stage diagnosis…
-
NVIDIA Expands Healthcare Reach with Amgen’s deCode Partnership at JP Morgan Conference
•
At the recent JP Morgan Healthcare Conference, US chip giant NVIDIA (NASDAQ: NVDA) announced a new collaboration with Amgen (NASDAQ: AMGN)’s subsidiary, deCode. This partnership will see deCode leverage NVIDIA’s advanced supercomputers and the BioNeMo generative artificial intelligence (AI) platform to bolster the development of its genomic foundational models. BioNeMo,…
-
Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis
•
Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ: GOOGL), has entered into its inaugural pharmaceutical collaborations, signing separate agreements with Eli Lilly (NYSE: LLY) and Novartis (NYSE: NVS). These partnerships are aimed at discovering small-molecule therapeutics for multiple undisclosed targets. Under the terms…
-
Menarini’s Stemline Signs $500M+ License with Insilico for Cancer Drug Candidate
•
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics, has entered an exclusive license agreement with China’s Insilico Medicine to develop a KAT6A inhibitor originating from Insilico’s AI-driven platform. The candidate, targeted for hormone-sensitive cancers and other oncological indications, shows promise as a potent KAT6A inhibitor based on preclinical data. KAT6A,…
-
Baidu Health and Chongqing’s Fifth People’s Hospital Collaborate on Integrated Medical Services
•
Baidu Health has entered into a partnership with the Fifth People’s Hospital of Chongqing, a Class 3A general hospital in China. The collaboration aims to combine the hospital’s disciplinary and location advantages with Baidu Health’s strengths in online diagnosis, treatment, digitalization, and artificial intelligence (AI) to establish an integrated online-offline…
-
Sanofi Broadens Collaboration with Exscientia, Licensing New Precision Drug Program
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has expanded its partnership with UK-based AI-driven precision drug design company Exscientia (NASDAQ: EXAI) by in-licensing a program in an undisclosed therapeutic area. This move builds on a 2022 agreement aimed at developing up to 15 novel small-molecule candidates across oncology and immunology. The…
-
MSD Partners with Owkin to Develop MSI-H Biomarker Screening for Cancers
•
US pharmaceutical company Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a partnership with French firm Owkin to develop and commercialize a pre-screening procedure for identifying the microsatellite instability- (MSI) H biomarker in various cancers. The initiative aims to test for MSI-H in endometrial, gastric, small intestinal, and…
-
Reetoo Biotechnology Boosts AI in Medical Diagnostics with $14 Million Funding Round
•
Shenzhen Reetoo Biotechnology Co., Ltd, a Chinese firm at the forefront of integrating artificial intelligence with medical diagnostics, has reportedly secured over RMB 100 million (USD 14 million) in a Series B2 financing round. The round was led by CAS Investment and a prominent Chinese fund, with additional participation from…
-
MSD to Migrate IT Systems to AWS, Aiming for Faster Drug Discovery and Clinical Trials
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced plans to transition a significant portion of its IT infrastructure to Amazon Web Services (AWS), a move aimed at enhancing efficiency in drug discovery and clinical trial development. This multiyear initiative, revealed by parent company Amazon (NASDAQ: AMZN) this week, will…
-
Insilico Medicine Launches Clinical Study for First-in-Class PHD Inhibitor ISM5411 in IBD
•
Insilico Medicine, a China-based biotech leveraging generative artificial intelligence (AI), has announced the initiation of a clinical study for its potential first-in-class PHD inhibitor, ISM5411, targeting inflammatory bowel disease (IBD). ISM5411 is an intestinal-restricted small-molecule inhibitor developed using Insilico’s Pharma.AI platform, featuring a novel molecular framework and a unique binding…
-
Boehringer Ingelheim Partners with Phenomic AI to Target Stroma-Rich Cancers
•
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Canada’s Phenomic AI to leverage the latter’s single-cell transcriptomics platform for the discovery of drug targets in stroma-rich cancers, including colorectal and pancreatic tumors. In return for the option to license the identified targets and secure development…
-
Xiamen Inno Medical Partners with Olympus to Advance AI in Digestive Endoscopy
•
Xiamen Inno Medical Technology Co., Ltd., a China-based specialist in artificial intelligence (AI) powered digestive endoscopy, has entered into a partnership with Olympus Corporation, a major player in the digestive endoscopy field. The collaboration aims to explore innovative applications and development of AI technology within the digestive endoscopy sector. Financial…
-
Genentech and NVIDIA Collaborate to Advance Drug Discovery with AI
•
Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has entered into a collaboration agreement with semiconductor manufacturer NVIDIA (NASDAQ: NVDA) to expedite drug discovery and development. This partnership aims to harness the power of artificial intelligence (AI) by integrating Genentech’s biological and molecular datasets with NVIDIA’s advanced supercomputing…
-
XtalPi Inc. and Singapore’s EDDC Broaden Collaboration in AI-Driven Drug Discovery
•
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has entered into a memorandum of understanding (MOU) with the Experimental Drug Development Centre (EDDC) in Singapore to form a collaborative partnership. The two entities have pledged to expand their collaboration to include the application of automated synthesis experiments and large…
-
AstraZeneca Launches Evinova to Enhance Global Clinical Development with Digital Health Solutions
•
UK-based AstraZeneca (AZ; NASDAQ: AZN) has launched Evinova, a digital health solutions provider, with the aim of supporting global clinical development. Evinova offers AI-enabled technologies and services to clinical trial (CT) sponsors, clinical research organizations (CROs), CT site care teams, and patients. The new business unit will initially focus on…
-
Winning Health Partners with Shanghai Seventh People’s Hospital on Medical AI Services
•
Shanghai-based medical information industry player, Winning Health (SHE: 300253), has announced a partnership with Shanghai Seventh People’s Hospital to focus on medical artificial intelligence (AI) services. Collaboration on Medical AI Development and ApplicationThe collaboration aims to deepen research and development, application, and implementation of medical AI technologies. Together, Winning Health…
-
Amgen Partners with PostEra for Small-Molecule Drug Discovery Initiative
•
Biopharmaceutical company Amgen (NASDAQ: AMGN) has entered into a drug discovery collaboration with US-based PostEra, covering up to five small-molecule programs. As part of the agreement, Amgen will also secure a future option to leverage PostEra’s AI technology for its own pipeline development. Financial Details and PostEra’s Track RecordWhile the…
-
Bayer Shifts Focus of Recursion Pharmaceuticals Collaboration to Precision Oncology
•
Germany-headquartered Bayer (ETR: BAYN) has announced a significant modification to its 2020 drug discovery collaboration with US biotechnology firm Recursion Pharmaceuticals (NASDAQ: RXRX). The partnership, which was initially focused on fibrosis, will now shift its attention to precision oncology. This strategic move will see the initiation of up to seven…
-
Suzhou Porton Biologics Partners with BioMap to Enhance AAV Vector Design in Gene Therapy
•
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with US biotech company BioMap, an AI-based drug discovery platform co-founded by Baidu’s CEO Robin Li and Baidu Ventures CEO Wei Liu. This collaboration aims to develop an AAV assembly efficiency model…
-
Sun Yat-sen Memorial Hospital Partners with Siemens Healthineers on Metaverse Visualization Surgery
•
China’s Sun Yat-sen Memorial Hospital, affiliated with Sun Yat-sen University, has entered into a strategic partnership with Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) at the 6th China International Import Expo (CIIE) in Shanghai. The collaboration focuses on the science research, application, and translation of metaverse visualization surgery,…
